4Ps medicine of the fatty liver: The research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics

EPMA Journal

Volumn 5, Issue 1, 2014, Pages

  Trovato, Francesca Maria ^a   Catalano, Daniela ^a   Musumeci, Giuseppe ^b   Trovato, Guglielmo M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adipose tissue; Diet; Fashion; Fatty liver; Interactome; Lifestyle; Liver fibrosis; Obesity; Suboptimal health

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ASCORBIC ACID; ATORVASTATIN; CHOLINE; EXENDIN 4; EZETIMIBE; FENOFIBRATE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; MONOUNSATURATED FATTY ACID; NICOTINIC ACID; OBETICHOLIC ACID; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; POLYPHENOL; PROBIOTIC AGENT; SILIBININ; SILYMARIN; SIMVASTATIN; TAURINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALSARTAN; VITAMIN D;

ADIPOSE TISSUE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; COFFEE; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DRUG MEGADOSE; EPIDEMIC; FATTY LIVER; HEALTH EDUCATION; HUMAN; HYPERTRANSAMINASEMIA; LACTOBACILLUS BULGARICUS; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; MEDICAL EDUCATION; MEDICAL RESEARCH; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STREPTOCOCCUS THERMOPHILUS; UNSPECIFIED SIDE EFFECT;

EID: 84927948542     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-5-21     Document Type: Review

References (166)

1. Cinti S Between brown and white: novel aspects of adipocyte differentiation. Ann Med 2011, 43(2):104-115.
2. Ukkola O, Santaniemi M Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med (Berl) 2002, 80(11):696-702
3. Di Chiara T, Argano C, Corrao S, Scaglione R, Licata G Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J NutrMetab 2012, 2012:175-245.
4. Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam Study. J Hepatol 2012, 57(6):1305-1311.
5. Milić S, Stimac D Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012, 30(2):158-162.
6. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, Jang EC Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol 2013, 19(3):266-272.
7. Janczyk W, Socha P Non-alcoholic fatty liver disease in children. Clin Res Hepatol Gastroenterol 2012, 36(3):297-300.
8. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58(11):1538-1544.
9. Negro F Hepatitis C virus-induced steatosis: an overview. Dig Dis 2010, 28(1):294-299.
10. Lazo M, Clark JM The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28(4):339-350.
11. Negro F: Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006, 12(42):6756-6765.
12. Atkinson RL: Human adenovirus-36 and non-alcoholic fatty liver disease. Liver Int 2010, 30(2):164-165.
13. Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Garozzo A, Castro A, Catalano D Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci 2012, 57(2):535-544.
14. Dhurandhar NV Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complicat 2013, 27(2):191-199.
15. Trovato GM, Martines GF, Pirri C, Trovato FM, Castro A, Garozzo A, Catalano D Obesity-independent association of human adenovirus Ad37 seropositivity with nonalcoholic fatty liver disease. J Clin Gastroenterol 2012, 46(6):e46-e54.
16. Hooper AJ, Adams LA, Burnett JR Genetic determinants of hepatic steatosis in man. J Lipid Res 2011, 52(4):593-617.
17. Anstee QM, Day CP The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10(11):645-655.
18. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI, Nonalcoholic Steatohepatitis Clinical Research Network: Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139(5):1567-1576.
19. Lallukka S, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013, 56(4):886-892.
20. Abenavoli L, Milic N, De Lorenzo A, Luzza F A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013, 43(1):65-67.
21. Malhi H, Guicciardi ME, Gores GJ Hepatocyte death: a clear and present danger. Physiol Rev 2010, 90(3):1165-1194.
22. Malhi H, Gores GJ Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
23. Farrell GC, Larter CZ Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
24. Anderson N, Borlak J Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008, 60(3):311-357.
25. Bradbury MW, Berk PD Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004, 8(3):639-671.
26. Smith BW, Adams LA Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011, 48(3):97-113.
27. Stefan N, Kantartzis K, Haring HU Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29:939-960.
28. Caturelli E, Squillante MM, Andriulli A, Cedrone A, Cellerino C, Pompili M, Manoja ER, Rapaccini GL Hypoechoic lesions in the 'bright liver': a reliable indicator of fatty change. A prospective study. J Gastroenterol Hepatol 1992, 7(5):469-472.
29. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
30. Gressner OA, Weiskirchen R, Gressner AM Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 2007, 6:7.
31. Urtasun R, Nieto N Hepatic stellate cells and oxidative stress. Rev Esp Enferm Dig 2007, 99(4):223-230.
32. Passos-Silva DG, Verano-Braga T, Santos RA Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond) 2013, 124(7):443-456.
33. Ignotz RA, Massagué J Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986, 261(9):4337-4345.
34. Jou J, Choi SS, Diehl AM Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):370-379.
35. Canbay A, Friedman S, Gores GJ Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39(2):273-278.
36. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007, 46(5):1509-1518.
37. Zheng RD, Chen ZR, Chen JN, Lu YH, Chen J Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2012, 2012:362147.
38. Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, Kitajima Y, Kuroki S, Ozaki I, Kawaguchi Y, Ide Y, Yasutake T, Iwakiri R, Mizuta T, Ono N, Fujimoto K Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J Gastroenterol Hepatol 2008, 23(6):908-913.
39. Subramanian V, Johnston RD, Kaye P, Aithal GP Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 37(4):455-463.
40. Sorbi D, Boynton J, Lindor KD The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94(4):1018-1022.
41. Angulo P, Keach JC, Batts KP, Lindor KD Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
42. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
43. Catalano D, Trovato GM, Martines GF, Randazzo M, Tonzuso A Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study. Liver Int 2008, 28:1280-1287.
44. Cobbold JF, Patel D, Taylor-Robinson SD Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques. J Gastroenterol Hepatol 2012, 27(8):1281-1292.
45. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC, Cosgrove DO, Blomley MJ Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005, 54:128-133.
46. Cobbold JF, Patel D, Fitzpatrick JA, Patel N, Crossey MM, Abdalla MS, Goldin RD, Vennart W, Thomas HC, Taylor-Robinson SD Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C. Hepatol Res 2012, 42(5):515-522.
47. Iijima H, Moriyasu F, Tsuchiya K, Suzuki S, Yoshida M, Shimizu M, Sasaki S, Nishiguchi S, Maeyama S Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007, 37(9):722-730.
48. Charatcharoenwitthaya P, Lindor KD Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007, 11(1):37-54.
49. Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, Kottilil S, Morse C, Dodd L, Kleiner D, Hadigan C Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol 2012, 199(1):2-7.
50. Bohte AE, van Werven JR, Bipat S, Stoker J The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011, 21(1):87-97.
51. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123(3):745-750.
52. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012, 55(1):199-208.
53. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134(4):960-974.
54. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012, 32(6):911-918.
55. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012, 81(3):e325-e331.
56. Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V, FLIP Consortium: Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One 2012, 7(3):e30325.
57. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137(3):865-872.
58. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010, 10:103.
59. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006, 40(6):535-542.
60. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854.
61. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ, European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713.
62. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006, 64(6):679-683.
63. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013, 37(4):392-400.
64. Yilmaz Y NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis 2012, 32(1):14-21
65. Lata J, Jurankova J, Kopacova M, Vitek P Probiotics in hepatology. World J Gastroenterol 2011, 17(24):2890-2896.
66. Conterno L, Fava F, Viola R, Tuohy KM Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? Genes Nutr 2011, 6(3):241-260
67. Machado MV, Cortez-Pinto H Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012, 11(4):440-449.
68. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
69. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, Day CP, McTernan PG Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010, 7:15.
70. Tan Y, Ge G, Pan T, Wen D, Gan J A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014, 9(8):e105192.
71. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50(6):1827-1838.
72. Dumas ME, Kinross J, Nicholson JK Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014, 146(1):46-62.
73. Kuepfer L, Kerb R, Henney AM Clinical translation in the virtual liver network. CPT Pharmacometrics Syst Pharmacol 2014, 3:e127.
74. Schleicher J, Guthke R, Dahmen U, Dirsch O, Holzhuetter HG, Schuster S A theoretical study of lipid accumulation in the liver-implications for nonalcoholic fatty liver disease. Biochim Biophys Acta 2014, 1841(1):62-69.
75. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, Greco AV, Gasbarrini G, Grieco A Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005, 9(5):265-268.
76. Enjoji M, Yasutake K, Kohjima M, Nakamuta M Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol. Int J Hepatol 2012, 2012:925807.
77. Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, Terasawa K, Shimada Y Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006, 41(10):971-980.
78. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295(5):G987-G995.
79. Maersk M, Belza A, Stødkilde-Jørgensen H, Ringgaard S, Chabanova E, Thomsen H, Pedersen SB, Astrup A, Richelsen B Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012, 95(2):283-289.
80. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009, 119(5):1322-1334.
81. Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, Bremer AA, Berglund L, McGahan JP, Havel PJ, Keim NL Consumption of fructosesweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 2012, 66(2):201-208.
82. Westerbacka J, Lammi K, Häkkinen AM, Rissanen A, Salminen I, Aro A, Yki-Järvine NH Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005, 90(5):2804-2809.
83. Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012, 18(41):5839-5847.
84. Musumeci G, Trovato FM, Pichler K, Weinberg AM, Loreto C, Castrogiovanni P Extra-virgin olive oil diet and mild physical activity prevent cartilage degeneration in an osteoarthritis model. An "in vivo" and "in vitro" study on lubricin expression. J Nutr Biochem 2013, 24:2064-2075.
85. Assy N, Nassar F, Nasser G, Grosovski M Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol 2009, 15(15):1809-1815.
86. Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007, 30:1717-1723.
87. Musumeci G, Trovato FM, Imbesi R, Castrogiovanni P Effects of dietary extra-virgin olive oil on oxidative stress resulting from exhaustive exercise in rat skeletal muscle: a morphological study. Acta Histochem 2013, 116(1):61-69.
88. Pascoli MD, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, Bosch J, García-Pagán JC Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013, 58(5):904-910.
89. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martínez JA, Portillo MP Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012, 107(2):202-210.
90. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, García-Urkia N, Sarasqueta C, Cosme A, Irastorza B, González A, Arenas JI Jr Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
91. Dunn W, Xu R, Schwimmer JB Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47(6):1947-1954.
92. Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009, 21(9):969-972.
93. Oliveira LP, de Jesús RP, Freire TO, Oliveira CP, Castro Lyra A, Lyra LG Possible molecular mechanisms soy-mediated in preventing and treating nonalcoholic fatty liver disease. Nutr Hosp 2012, 27(4):991-998.
94. Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS, Yang SS Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Nutrition 2011, 27(9):943-948.
95. Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT, Wang D, Wei Y, Jiang H, Orlicky DJ, Petersen DR, Pagliassotti MJ, Maclean KN Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011, 301(6):R1710-R1722.
96. Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, Amzolini A, Ben-Amor I, Saint-Paul MC, Mariné-Barjoan E, Pariente A, Gugenheim J, Gual P, Tran A Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012, 57(5):1090-1096.
97. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 35(1):76-82.
98. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2010, 55(11):3200-3206.
99. Corbin KD, Zeisel SH Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012, 28(2):159-165.
100. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011, 9:85.
101. Trovato GM Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J 2012, 3(1):8.
102. Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindström T, Nystrom FH, Fast Food Study Group: Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008, 57(5):649-654.
103. Thoma C, Day CP, Trenell MI Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012, 56(1):255-266.
104. Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, Choudhuri G Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 21:191-198.
105. Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G Life style modification improves insulin resistance and liver histology in patients with nonalcoholic fatty liver disease. World J Hepatol 2012, 4(7):209-217.
106. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB, NASH CRN Research Group: Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011, 106(3):460-468.
107. Türkay C, Ozol D, Kasapoğlu B, Kirbas I, Yi{dotless}ldi{dotless}ri{dotless}m Z, Yiğitoğlu R Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care 2012, 57(2):244-249.
108. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002, 165(5):677-682.
109. Shpirer I, Copel L, Broide E, Elizur A Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung 2010, 188(4):301-307.
110. Dimitrov DV, Ivanov V, Atanasova M Advantages of bariatric medicine for individualized prevention and treatments: multidisciplinary approach in body culture and prevention of obesity and diabetes. EPMA J 2011 Sep, 2(3):271-276.
111. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRN: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685.
112. Pais R, Moraru I, Ratziu V Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011, 4(5):325-334.
113. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29(2):172-182.
114. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A The role of metformin in the management of NAFLD. Exp Diabetes Res 2012, 2012:716404.
115. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010, 22(1):18-23.
116. Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 2010, 9:29.
117. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106(1):71-77.
118. Nakajima K Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease. Int J Hepatol 2012, 2012:950693.
119. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010, 95(6):2727-2735.
120. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008, 40(3):200-205.
121. Schupp M, Janke J, Clasen R, Unger T, Kintscher U Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptorgamma activity. Circulation 2004, 109(17):2054-2057.
122. Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, Chen B, Li X, Zu M, Zhou D, Guo J, Yang H, Du G Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 2012, 685(1-3):156-164.
123. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2012, 24(2):164-171.
124. Lee J, Hong SW, Rhee EJ, Lee WY GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 2012, 36(4):262-267.
125. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24(1):275-286.
126. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012, 7(12):e50117.
127. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011, 19(12):2310-2315.
128. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
129. Adams LA, Angulo P, Petz J, Keach J, Lindor KD A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010, 4(3):628-633.
130. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J FRESGUN: A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011, 54(5):1011-1019.
131. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145(3):574.82.e1.
132. Assy N, Hussein O, Abassi Z Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007, 56(3):443-444.
133. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49(1):80-86.
134. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008, 24(7):1919-1929.
135. Préaux AM, Mallat A, Rosenbaum J, Zafrani ES, Mavier P Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997, 26(2):315-322.
136. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ: Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54(5):1610-1619.
137. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009, 139(5):905-911.
138. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011, 15(9):1090-1095.
139. Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr 2014. doi:10.1016/j.clnu.2014.01.018.
140. Trovato GM, Catalano D, Martines GF, Pirri C, Trovato FM Western dietary pattern and sedentary life: independent effects of diet and physical exercise intensity on NAFLD. Am J Gastroenterol 2013, 108(12):1932-1933.
141. Catalano D, Trovato GM, Pace P, Martines GF, Trovato FM Mediterranean diet and physical activity: an intervention study. Does olive oil exercise the body through the mind? Int J Cardiol 2013, 168(4):4408-4409.
142. Trovato GM, Catalano D, Martines GF, Pace P, Trovato FM Mediterranean diet: relationship with anxiety and depression. Ann Neurol 2014, 75(4):613.
143. Trovato GM, Martines GF, Trovato FM, Catalano D Relation of the traditional Mediterranean diet to cerebrovascular disease in a Mediterranean population. Am J Epidemiol 2013, 178(4):661.
144. Trovato GM, Martines GF, Garozzo A, Tonzuso A, Timpanaro R, Pirri C, Trovato FM, Catalano D Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int 2010, 30(2):184-190.
145. Trovato GM, Pace P, Cangemi E, Martines GF, Trovato FM, Catalano D Gender, lifestyles, illness perception and stress in stable atrial fibrillation. Clin Ter 2012, 163(4):281-286.
146. Trovato GM, Pace P, Martines GF, Trovato FM, Pirri C, Catalano D Stress, abdominal obesity and intrarenal resistive index in essential hypertension. Clin Ter 2012, 163(4):299-305.
147. Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int 2011, 5(3):822-829.
148. Catalano D, Trovato GM, Spadaro D, Martines GF, Garufi G, Tonzuso A, Grasso D, Sciacchitano SG Insulin resistance in postmenopausal women: concurrent effects of hormone replacement therapy and coffee. Climacteric 2008, 11(5):373-382.
149. Trovato GM, Catalano D, Caruso G, Squatrito R, Venturino M, Degano C, Di Fazzio S Relationship between cardiac function and insulin resistance in obese patients. Diabetes Nutr Metab 2001, 14(6):325-328.
150. Trovato G, Brischetto D, Pace P, Fabio Martines G Perceived body weight status of youngsters interferes with headache in obese and non-obese subjects. Headache 2014, 54(6):1062-1063.
151. Trovato G, Brischetto D, Martines GF Teens' obesity, noise and sleep deprivation: a perverse liaison. Let's move beyond "movida". Obesity (Silver Spring) 2014, 22(5):1209.
152. Golubnitschaja O, Kinkorova J, Costigliola V Predictive, preventive and personalised medicine as the hardcore of 'Horizon 2020': EPMA position paper. EPMA J 2014, 5(1):6.
153. Lemke HU, Golubnitschaja O Towards personal health care with modelguided medicine: long-term PPPM-related strategies and realisation opportunities within 'Horizon 2020'. EPMA J 2014, 5(1):8.
154. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013, 2013(5):109-113.
155. Roberti di Sarsina P, Alivia M, Guadagni P Traditional, complementary and alternative medical systems and their contribution to personalisation, prediction and prevention in medicine-person-centred medicine. EPMA J 2012, 3(1):15.
156. Fang FC, Steen RG, Casadevall A Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci USA 2012, 109(42):17028-17033.
157. Godecharle S, Nemery B, Dierickx K Guidance on research integrity: no union in Europe. Lancet 2013, 381(9872):1097-1098.
158. Yan YX, Liu YQ, Li M, Hu PF, Guo AM, Yang XH, Qiu JJ, Yang SS, Shen J, Zhang LP, Wang W Development and evaluation of a questionnaire for measuring suboptimal health status in urban Chinese. J Epidemiol 2009, 19(6):333-341.
159. Ko GT, Chan JC, Chan AW, Wong PT, Hui SS, Tong SD, Chow F, Chan CL Low levels of awareness of suboptimal health conditions in a high-risk working population: the better health for better Hong Kong health promotion campaign. Int J Behav Med 2007, 14(2):63-69.
160. Bi J, Huang Y, Xiao Y, Cheng J, Li F, Wang T, Chen J, Wu L, Liu Y, Luo R, Zhao X Association of lifestyle factors and suboptimal health status: a cross-sectional study of Chinese students. BMJ Open 2014, 4(6):e005156.
161. Turer CB, Lin H, Flores G Health status, emotional/behavioral problems, health care use, and expenditures in overweight/obese US children/adolescents. Acad Pediatr 2013, 13(3):251-258.
162. Persson R, Cleal B, Bihal T, Hansen SM, Jakobsen MØ, Villadsen E, Andersen LL Why do people with suboptimal health avoid health promotion at work?. Am J Health Behav 2013, 37(1):43-55.
163. Poikolainen K, Vartiainen E Wine and good subjective health. Am J Epidemiol 1999, 150(1):47-50.
164. Rosenberger M Sedentary behavior: target for change, challenge to assess. Int J Obes Suppl 2012, 2(Suppl 1):S26-S29.
165. Spruyt K, Gozal D The underlying interactome of childhood obesity: the potential role of sleep. Child Obes 2012, 8(1):38-42.
166. Trovato G, Pace P, Martines GF, Brischetto D Mala-movida: late bed-timing and wake-up induce malnutrition and underweight in youngsters. Chronobiol Int 2014, 31(8):945-946.